CN101683404A - Traditional Chinese medicine composition for treating dampness and heat in liver and gallbladder and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating dampness and heat in liver and gallbladder and preparation method thereof Download PDFInfo
- Publication number
- CN101683404A CN101683404A CN200810211655A CN200810211655A CN101683404A CN 101683404 A CN101683404 A CN 101683404A CN 200810211655 A CN200810211655 A CN 200810211655A CN 200810211655 A CN200810211655 A CN 200810211655A CN 101683404 A CN101683404 A CN 101683404A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- weight portion
- medicine composition
- weight portions
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 210000004185 liver Anatomy 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 210000000232 gallbladder Anatomy 0.000 title claims abstract description 9
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000000463 material Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims description 30
- 239000002775 capsule Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000001291 vacuum drying Methods 0.000 claims description 9
- 239000012567 medical material Substances 0.000 claims description 7
- 239000011812 mixed powder Substances 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 13
- 208000005252 hepatitis A Diseases 0.000 abstract description 9
- 208000024891 symptom Diseases 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 206010059193 Acute hepatitis B Diseases 0.000 abstract description 5
- 208000037628 acute hepatitis B virus infection Diseases 0.000 abstract description 5
- 208000002193 Pain Diseases 0.000 abstract description 4
- 230000036407 pain Effects 0.000 abstract description 4
- 230000004596 appetite loss Effects 0.000 abstract description 3
- 201000006549 dyspepsia Diseases 0.000 abstract description 3
- 235000021266 loss of appetite Nutrition 0.000 abstract description 3
- 208000019017 loss of appetite Diseases 0.000 abstract description 3
- 206010013954 Dysphoria Diseases 0.000 abstract description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 2
- 235000019658 bitter taste Nutrition 0.000 abstract description 2
- 206010016256 fatigue Diseases 0.000 abstract description 2
- 230000006870 function Effects 0.000 abstract description 2
- 208000026435 phlegm Diseases 0.000 abstract description 2
- 230000035807 sensation Effects 0.000 abstract description 2
- 235000019615 sensations Nutrition 0.000 abstract description 2
- 210000002700 urine Anatomy 0.000 abstract description 2
- 206010000060 Abdominal distension Diseases 0.000 abstract 1
- 206010008479 Chest Pain Diseases 0.000 abstract 1
- 235000002991 Coptis groenlandica Nutrition 0.000 abstract 1
- 244000247747 Coptis groenlandica Species 0.000 abstract 1
- 208000006083 Hypokinesia Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 240000002853 Nelumbo nucifera Species 0.000 abstract 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 208000004880 Polyuria Diseases 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 230000035619 diuresis Effects 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 206010028851 Necrosis Diseases 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 230000017074 necrotic cell death Effects 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 206010019799 Hepatitis viral Diseases 0.000 description 7
- 208000006454 hepatitis Diseases 0.000 description 7
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 7
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 7
- 201000001862 viral hepatitis Diseases 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 231100000354 acute hepatitis Toxicity 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 206010019847 hepatosplenomegaly Diseases 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 3
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000000622 irritating effect Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 101710142246 External core antigen Proteins 0.000 description 2
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000239222 Tachypleus Species 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 231100000291 zonal necrosis Toxicity 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines:coptis, red peony root, lotus plumule, rhubarb, spora lygodii and indigo naturalis. The traditional Chinese medicine composition has the functions of clearing away heat and toxic material and promoting diuresis and eliminating phlegm, and is clinically used for patients with acute hepatitis A and acute hepatitis B which belong to the dampness and heat in the liver and gallbladder and have the symptoms of distending pain in hypochondrium, dysphoria with smothery sensation, bitterness in the mouth, nausea, indigestion and loss of appetite, chest distress, abdominal distension, fatigue, hypodynamia, dark urine, and the like.
Description
Technical field
The invention provides a kind of Chinese medicine composition, particularly relate to a kind of Chinese medicine composition for the treatment of syndrome of dampness-heat of liver and gallbladder.
Background technology
Acute viral hepatitis is mainly caused by the hepatitis virus A that has a liking for liver, B, C, D, E; Some non-special viruses of having a liking for liver also can start an inflammation of the liver as cytomegalovirus, Epstain-Barr virus, herpes simplex virus etc., but rare.The acute viral hepatitis that China takes place at present mainly is a hepatitis A; Viral hepatitis can be divided into the infectious hepatitis of intestinal biography property and the serum hepatitis of blood biography property, and the hepatitis pathological changes of intestinal biography property is from limitting the developed into chronic hepatitis of blood biography property.
The traditional Chinese medical science thinks that focusing on of acute hepatitis treatment is eliminating evil.Damp and hot and epidemic disease poison is morbific exopathogenic factor, and the imbalance of liver,spleen,kidney three dirty functions, or QI and blood deficiency is the main endogenous cause of ill of morbidity.The most true card of acute hepatitis though have visceral dysfunction and QI and blood to change, is characterized in: " the evil Sheng just do not declined ".Therefore, treatment focus on eliminating evil.Clinically, often can see general lassitude, weakly breathe hard, the resembling of weakness such as indigestion and loss of appetite, soreness of the waist and knees, yet this is because due to the damp and hot heresy, be " due to illness and empty ", healthy energy is not weak, can't see that virtual image is absurd throwing tonic, in order to avoid help the wet heat that helps, cause the trouble of " close door and stay the bandit ", should be eliminating evil as treatment emphasis, " eliminating evil " promptly to set upright.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine composition for the treatment of syndrome of dampness-heat of liver and gallbladder.
Another object of the present invention provides a kind of preparation method for the treatment of the Chinese medicine composition of syndrome of dampness-heat of liver and gallbladder.
The present invention also aims to provide the application of a kind of Chinese medicine composition in preparation treatment acute hepatitis A medicine.
The present invention also aims to provide the application of a kind of Chinese medicine composition in preparation treatment acute hepatitis B medicine.
The objective of the invention is to be achieved through the following technical solutions:
The Chinese medicine composition of treatment syndrome of dampness-heat of liver and gallbladder of the present invention, make by following raw materials in weight portion medicine:
Rhizoma Coptidis 3-15 weight portion, Radix Paeoniae Rubra 10-25 weight portion, Plumula Nelumbinis 5-12 weight portion, Radix Et Rhizoma Rhei 2-15 weight portion, Spora Lygodii 10-40 weight portion, Indigo Naturalis 5-15 weight portion.
The preferred following raw materials in weight portion medicine of above-mentioned Chinese medicine composition is made:
Rhizoma Coptidis 4-10 weight portion, Radix Paeoniae Rubra 15-20 weight portion, Plumula Nelumbinis 6-10 weight portion, Radix Et Rhizoma Rhei 6-10 weight portion, Spora Lygodii 10-20 weight portion, Indigo Naturalis 5-10 weight portion.
The preparation method of above-mentioned Chinese medicine drug composition may further comprise the steps:
A, get Rhizoma Coptidis, Radix Paeoniae Rubra, Plumula Nelumbinis mixed powder and be broken into coarse powder, add 10～16 times of water gagings and decoct each 1～3 hour 2～4 times, filter, collecting decoction, relative density is 1.08～1.14 extractum when being concentrated into 50 ℃, 50～70 ℃ of vacuum dryings are ground into fine powder, and are standby;
B, Radix Et Rhizoma Rhei, Indigo Naturalis, Spora Lygodii pulverizing medicinal materials are crossed 80 mesh sieves, and be standby;
C, with step a gained dry extract fine powder and step b gained medical material fine powder, mix homogeneously is made tablet, capsule, pill, granule, promptly.
Above-mentioned steps a is preferably coarse powder is added 12 times of water gagings decoctions 3 times, and each 1 hour, filter, collecting decoction, relative density is 1.08～1.14 extractum when being concentrated into 50 ℃, 60 ℃ of vacuum dryings.
Rhizoma Coptidis heat clearing and damp drying in the pharmaceutical composition prescription of the present invention, eliminating fire and detoxication; The Radix Paeoniae Rubra clearing away heat and cooling blood, eliminating stasis to stop pain; The Plumula Nelumbinis clearing away heart-fire for tranquillization, restoring normal coordination between the heart and kidney, unsmoothing the sperm and stopping bleeding; The Radix Et Rhizoma Rhei purging heat and dredging bowels, removing pathogenic heat from blood and toxic substance from the body, eliminating blood stasis and inducing menstruation; The Spora Lygodii eliminating damp-heat, treating stranguria pain relieving; The Indigo Naturalis heat-clearing and toxic substances removing, removing heat from blood, arresting convulsion.Full side plays heat-clearing and toxic substances removing, the effect that dampness removing reduces phlegm altogether.Be used for acute first, the hepatitis B person that belongs to the syndrome of dampness-heat of liver and gallbladder, disease is seen association's rib distending pain, the dysphoria with smothery sensation bitter taste, and it is indigestion and loss of appetite to feel sick, and the vexed abdominal distention of wrist is refreshing tired weak, yellowish or reddish urine.
Following experimental example is used to further specify but is not limited to the present invention.
Experimental example 1 pharmacodynamics test
One, medicine of the present invention is to the protective effect of acute liver damage due to the thioacetamide
1 materials and methods
1.1 laboratory animal is selected 40 of SD rats for use, body weight 200-220g, male and female dual-purpose, cleaning level.
1.2 trial drug; Medicine of the present invention is according to the Chinese medicinal composition capsules agent of the present invention of embodiment 1 success preparation.The positive control medicine, commercially available liver heat removing toxic capsule is produced the accurate word Z20030010 of traditional Chinese medicines by Hangzhou miracle king pharmaceutcal corporation, Ltd.
1.3 main agents: thioacetamide, chemical reagents corporation provides by Beijing; The Fine Chemical Works production of cultivating people of ability of pentobarbital sodium, Tong County, Beijing; Tachypleus amebocyte lysate box, she changes clinical medicine scientific ﹠ technical corporation (Shanghai City medical science assay office) by Shanghai provides; ALT (ALT), asparagine acidic group conversion enzyme (AST) test kit are provided by Roche company; Tumor necrosis factor one Ot (TNF-n) radioimmunological kit is provided by the Beijing North biotechnology research.
1.4 key instrument: Reicheit-Jung2040 microtome: Germany; BH-2 optical microscope: Olympus, Japan; Qwin image analysis system: Leica, Germany; The 752C ultraviolet-uisible spectrophotometer; Shanghai the 3rd analytical tool factory; GC-911 radioimmunity enumerator: University of Science and Technology of China,technology industry Corp; Hitachi's 7170 full-automatic biological analysers: Japan.
1.5 grouping and processing are divided into 4 groups at random with 40 rats: 10 of normal control groups, 10 of model group, 10 of medicine groups of the present invention, 10 of positive controls.Medicine of the present invention is irritated stomach according to the 0.27g/kg body weight, and 1 hour pneumoretroperitoneum injection thioacetamide (TAA) 600mg/kg body weight gives medicine of the present invention respectively at irritating stomach once more after 6 hours, 12 hours.The positive control medicine is irritated stomach according to the 0.27g/kg body weight, and 1 hour pneumoretroperitoneum injection thioacetamide (TAA) 600mg/kg body weight gives medicine of the present invention respectively at irritating stomach once more after 6 hours, 12 hours.Model group is irritated stomach and is given isometric distilled water, 1 hour pneumoretroperitoneum injection TAA, and dosage is the same, gives distilled water respectively at irritating stomach once more after 6 hours, 12 hours; The normal saline of normal control group lumbar injection equivalent.The normal saline of normal control group lumbar injection equivalent.Inject after 24 hours, with the pentobarbital sodium intraperitoneal injection of anesthesia of 45mg/kg body weight, in the aseptic blood of getting of ventral aorta, separation of serum, blood plasma are respectively applied for the mensuration of A, AST, TNF.oL and endotoxin content with each group rat.Get liver, use 10% formaldehyde fixed.
1.6 index determining is the PATHOMORPHOLOGICAL OBSERVATION OF PULLORUM of hepar damnification situation 1.: get liver, routine is drawn materials, paraffin embedding, HE dyeing.Under the light microscopic it is carried out PATHOMORPHOLOGICAL OBSERVATION OF PULLORUM, and measure its damaged area percentage ratio with the Qwin image analysis system.Assay method: under 200 times of light microscopics, its damaged area percentage ratio is measured in 10 visuals field of picked at random, gets its meansigma methods.2. serum alt, AST active concentration determination carry out with Hitachi's 7170 automatic clinical chemistry analyzers.3. TNF.OL assay in the serum according to the appended description of test kit, carries out with GC-911 radioimmunity enumerator.3. endotoxin content is measured according to the appended description of test kit in the blood plasma, carries out with the 752C ultraviolet-uisible spectrophotometer.
2 results
2.1 morphological changes of various tissue components
1. normal control group: liver structure is normal, and tunicle does not thicken, and the lobule boundary is clear, and the liver plate is the center with the lobule central vein, is radial arrangement.The liver plate is a cell thickness.Sinus hepaticus is not seen expansion, does not also have narrow.The lobules of liver parenchyma is not seen degeneration and necrosis.The central vein wall does not have and thickens, and the portal area tee pipe is high-visible, and no lymphocytic infiltration is not seen connective tissue proliferation.Interstitial cell does not increase.
2. model group; Liver structure is normal substantially, and tunicle does not thicken, and the lobules of liver boundary is still clear, and the liver plate is not seen and thickened.Visible multiple kitchen range shape blister degeneration of liver parenchyma and balloon sample become, and visible fresh point-like, kitchen range shape, band shape and bridging necrosis.Necrosis region visible cell fragment, and see neutrophilic granulocyte, a small amount of eosinophilic granulocyte and lymphocytic infiltration.Visible regression of the inflammatory cell of infiltration and karyorrhexis.Visible circular eosinophilic body in the necrosis region.Point, the necrosis of kitchen range shape are more common in around the other sublobular vein of central vein, seriously locate visible lobule center band and are zonal necrosis, and necrosis region can link to each other with contiguous central zone or peripheral band sometimes, constitutes bridging necrosis.
3. medicine group rat pathology finding of the present invention is similar to model group, but the necrosis of some kitchen range shape, central zone necrosis and bridging necrosis are light than model group all.
4. positive drug control rats pathology finding is similar to model group, but the necrosis of some kitchen range shape, central zone necrosis and bridging necrosis are light than model group all.
Further the graphical analysis result shows, the hepar damnification area of medicine group rat of the present invention is starkly lower than model group.See Table 1.
Table 1 is respectively organized the degree of impairment of rat liver
| Group | ??n | Hepar damnification area (%) |
| The normal control group | ??10 | ??0 |
| Model group | ??10 | ??14.99±2.73 |
| Medicine group of the present invention | ??10 | ?9.55±2.13△△ |
| The positive drug matched group | ??10 | ?11.37±2.32△△ |
Compare △ △ P＜0.01 with model group
2.2 medicine of the present invention the results are shown in Table 2 to the active influence of ALT, AST in the hepatic injury rat blood serum.
Table 2 is respectively organized the active variation of ALT in the rat blood serum, AST (x ± s)
| Group | ??n | ??ALT(U/L) | ??AST(U/L) |
| The normal control group | ??10 | ??54.40±12.44 | ??165.20±50.84 |
| Model group | ??10 | ??153.11±67.05** | ??987.78±393.47** |
| Medicine group of the present invention | ??10 | ??99.65±66.52 | ??393.44±273.29*△△ |
| The positive drug matched group | ??10 | ??123.34±68.17 | ??520.54±301.25*△△ |
Compare * P＜0.05, * * P＜0.01 with the normal control group; Compare △ △ P＜0.01 with model group
2.3 respectively organizing TNF-a in the rat serum, endotoxin content changes and sees Table 3.
Table 3 is respectively organized the variation (x ± s) of TNF-a in the rat serum, endotoxin content
| Group | ??n | ??TNF-a(fmol/ml) | Endotoxin (Ru/ml) |
| The normal control group | ??10 | ??3.39±9.974 | ??0.16±0.06 |
| Model group | ??10 | ??5.90±0.69** | ??1.59±0.22** |
| Medicine group of the present invention | ??10 | ??4.36±0.78*△△ | ??0.99±0.28**△△ |
| The positive drug matched group | ??10 | ??4.85±0.71*△△ | ??1.21±0.24**△△ |
Compare * P＜0.05 with the normal control group.* P＜0.01; Compare △ △ P (0.01 with model group
Medicine of the present invention has the endogenous toxin of removing rope, reduces tumor necrosis factor content, protects hepatocellular remarkable effect, and its effect is better than the positive control medicine.
The clinical efficacy of experimental example 2 treatment acute hepatitis As
1. object and method
The acute hepatitis A patient diagnosis meets " scheme of preventing and treating of viral hepatitis " standard of the 6th the national viral hepatitis meeting revision in nineteen ninety Shanghai 1.1 object is in hospital.Hepatitis A 16 examples, matched group 21 examples, two groups age, sex and sick plant to constitute etc. have comparability through chi-square criterion.
1.2 oral Chinese medicinal composition capsules agent of the present invention (0.5g/ grain) is organized in the method treatment, one time 2, three times on the one, 1 month was 1 course of treatment; The oral liver heat removing toxic capsule of matched group (the 0.5g/ grain is produced the accurate word Z20030010 of traditional Chinese medicines by Hangzhou miracle king pharmaceutcal corporation, Ltd), one time 2, three times on the one, 1 month was 1 course of treatment.
1.3 criterion of therapeutical effect is produce effects 1.: the course of treatment is when finishing, clinical symptom disappearance or obviously improvement, hepatosplenomegaly bounces back to some extent, ALT and Sb reduce to normal range. and 2. effective: clinical symptoms takes a turn for the better, the hepatosplenomegaly no change, ALT and Sb reduce more than 50% before the treatment. and 3. invalid: clinical symptoms does not have and is clearly better, and ALT and Sb level reduce less than 50% before the treatment, no change or increase the weight of to some extent. and total effective rate is that produce effects adds effectively.
2. result
Acute hepatitis A 16 examples, produce effects 10 examples (62.4%), effective 3 examples (18.8%), invalid 3 examples (18.8%), effective percentage 81.2%. acute hepatitis A 21 examples, produce effects 11 examples (52.4%), effective 3 examples (14.3%), invalid 7 examples (33.3%), effective percentage 66.7%.
Find out by above result of the test, acute hepatitis A Chinese medicine composition curative effect of the present invention all significantly is better than the liver heat removing toxic capsule.
The clinical efficacy of experimental example 3 treatment acute hepatitis Bs
1. object and method
The object acute hepatitis B patient diagnosis of being in hospital meets " scheme of preventing and treating of viral hepatitis " standard of the national viral hepatitis meeting revision in nineteen ninety the 6th in Shanghai.Hepatitis B 30 examples, matched group 25 examples, two groups age, sex and sick plant to constitute etc. have comparability through chi-square criterion.
1.2 oral Chinese medicinal composition capsules agent of the present invention (0.5g/ grain) is organized in the method treatment, one time 2, three times on the one, 2 months was 1 course of treatment; The oral liver heat removing toxic capsule of matched group (the 0.5g/ grain is produced the accurate word Z20030010 of traditional Chinese medicines by Hangzhou miracle king pharmaceutcal corporation, Ltd), one time 2, three times on the one, 2 months was 1 course of treatment.
1.3 criterion of therapeutical effect is produce effects 1.: the course of treatment is when finishing, clinical symptom disappearance or obviously improvement, hepatosplenomegaly bounces back to some extent, ALT and Sb reduce to normal range. and 2. effective: clinical symptoms takes a turn for the better, the hepatosplenomegaly no change, ALT and Sb reduce more than 50% before the treatment. and 3. invalid: clinical symptoms does not have and is clearly better, and ALT and Sb level reduce less than 50% before the treatment, no change or increase the weight of to some extent. and total effective rate is that produce effects adds effectively.
2. result
Acute hepatitis B 30 examples, produce effects 16 examples (53.3%), effective 12 examples (40.0%), invalid 2 examples (6.7%), effective percentage is 93.3%; Matched group 25 examples, produce effects 12 examples (48.0%), effective 4 examples (16.0%), invalid 9 examples (36.0%), effective percentage is that 64.0%. hepatitis B patient has 12 routine HBeAg to be positive, finishing cloudy commentaries on classics of back check 8 examples the course of treatment. matched group hepatitis B patient has the 10 routine HBeAg positives, finishes cloudy commentaries on classics of check 2 examples the course of treatment. and there were significant differences for the negative conversion rate between two groups.
Find out by above result of the test, acute hepatitis B Chinese medicine composition curative effect of the present invention all significantly is better than the liver heat removing toxic capsule.
The specific embodiment
Embodiment 1 capsule
Rhizoma Coptidis 100g, Radix Paeoniae Rubra 200g, Plumula Nelumbinis 80g, Radix Et Rhizoma Rhei 80g, Spora Lygodii 150g, Indigo Naturalis 60g.
Get Rhizoma Coptidis, Radix Paeoniae Rubra, Plumula Nelumbinis mixed powder and be broken into coarse powder, add 12 times of water gagings and decoct three times, each 1 hour, filter, collecting decoction, relative density is 1.08～1.14 extractum when being concentrated into 50 ℃, 60 ℃ of vacuum dryings are ground into fine powder, and are standby; Radix Et Rhizoma Rhei, Indigo Naturalis, Spora Lygodii pulverizing medicinal materials are crossed 80 mesh sieves, and be standby; With gained dry extract fine powder and medical material fine powder, mix homogeneously, filled capsules is made 1000, promptly.
Embodiment 2 capsules
Rhizoma Coptidis 150g, Radix Paeoniae Rubra 150g, Plumula Nelumbinis 150g, Radix Et Rhizoma Rhei 150g, Spora Lygodii 150g, Indigo Naturalis 150g.
Get Rhizoma Coptidis, Radix Paeoniae Rubra, Plumula Nelumbinis mixed powder and be broken into coarse powder, add 12 times of water gagings and decoct three times, each 1 hour, filter, collecting decoction, relative density is 1.08～1.14 extractum when being concentrated into 50 ℃, 60 ℃ of vacuum dryings are ground into fine powder, and are standby; Radix Et Rhizoma Rhei, Indigo Naturalis, Spora Lygodii pulverizing medicinal materials are crossed 80 mesh sieves, and be standby; With gained dry extract fine powder and medical material fine powder, mix homogeneously, filled capsules is made 1000, promptly.
Embodiment 3 capsules
Rhizoma Coptidis 200g, Radix Paeoniae Rubra 250g, Plumula Nelumbinis 50g, Radix Et Rhizoma Rhei 80g, Spora Lygodii 60g, Indigo Naturalis 50g.
Get Rhizoma Coptidis, Radix Paeoniae Rubra, Plumula Nelumbinis mixed powder and be broken into coarse powder, add 12 times of water gagings and decoct three times, each 1 hour, filter, collecting decoction, relative density is 1.08～1.14 extractum when being concentrated into 50 ℃, 60 ℃ of vacuum dryings are ground into fine powder, and are standby; Radix Et Rhizoma Rhei, Indigo Naturalis, Spora Lygodii pulverizing medicinal materials are crossed 80 mesh sieves, and be standby; With gained dry extract fine powder and medical material fine powder, mix homogeneously, filled capsules is made 1000, promptly.
Embodiment 4 tablets
Rhizoma Coptidis 80g, Radix Paeoniae Rubra 180g, Plumula Nelumbinis 80g, Radix Et Rhizoma Rhei 70g, Spora Lygodii 180g, Indigo Naturalis 70g.
Get Rhizoma Coptidis, Radix Paeoniae Rubra, Plumula Nelumbinis mixed powder and be broken into coarse powder, add 12 times of water gagings and decoct three times, each 1 hour, filter, collecting decoction, relative density is 1.08～1.14 extractum when being concentrated into 50 ℃, 60 ℃ of vacuum dryings are ground into fine powder, and are standby; Radix Et Rhizoma Rhei, Indigo Naturalis, Spora Lygodii pulverizing medicinal materials are crossed 80 mesh sieves, and be standby; With gained dry extract fine powder and medical material fine powder, mix homogeneously, common process are made 1000, promptly.
Embodiment 5 granules
Rhizoma Coptidis 60g, Radix Paeoniae Rubra 180g, Plumula Nelumbinis 70g, Radix Et Rhizoma Rhei 70g, Spora Lygodii 130g, Indigo Naturalis 80g.
Get Rhizoma Coptidis, Radix Paeoniae Rubra, Plumula Nelumbinis mixed powder and be broken into coarse powder, add 12 times of water gagings and decoct three times, each 1 hour, filter, collecting decoction, relative density is 1.08～1.14 extractum when being concentrated into 50 ℃, 60 ℃ of vacuum dryings are ground into fine powder, and are standby; Radix Et Rhizoma Rhei, Indigo Naturalis, Spora Lygodii pulverizing medicinal materials are crossed 80 mesh sieves, and be standby; With gained dry extract fine powder and medical material fine powder, mix homogeneously, common process is made granule.
Embodiment 6 embodiment 1-5 are to the active influence of ALT, AST in the hepatic injury rat blood serum
1, material method
Identical with experimental example 1 pharmacodynamics test method.
2, result
Table four is respectively organized the active variation of ALT in the rat blood serum, AST (x ± s)
| Group | ??n | ??ALT(U/L) | ??AST(U/L) |
| The normal control group | ??10 | ??52.50±10.24 | ??158.35±50.46 |
| Model group | ??10 | ??149.08±68.42** | ??979.87±390.25** |
| Embodiment 1 capsule | ??10 | ??98.76±65.38 | ??391.15±272.40*△△ |
| Embodiment 2 capsules | ??10 | ??130.52±67.50 | ??490.70±279.65*△△ |
| Embodiment 3 capsules | ??10 | ??128.52±67.50 | ??516.70±299.68*△△ |
| Embodiment 4 tablets | ??10 | ??110.23±55.50 | ??415.15±189.40 |
| Embodiment 5 granules | ??10 | ??120.34±57.50 | ??430.56±230.40 |
Compare * P＜0.05, * * P＜0.01 with the normal control group; Compare △ △ P＜0.01 with model group
Claims (7)
1, a kind of Chinese medicine composition that is used for the treatment of syndrome of dampness-heat of liver and gallbladder is characterized in that this Chinese medicine composition made by following raw materials in weight portion medicine:
Rhizoma Coptidis 3-15 weight portion, Radix Paeoniae Rubra 10-25 weight portion, Plumula Nelumbinis 5-12 weight portion, Radix Et Rhizoma Rhei 2-15 weight portion, Spora Lygodii 10-40 weight portion, Indigo Naturalis 5-15 weight portion.
2, Chinese medicine composition according to claim 1 is characterized in that this Chinese medicine composition made by following raw materials in weight portion medicine:
Rhizoma Coptidis 4-10 weight portion, Radix Paeoniae Rubra 15-20 weight portion, Plumula Nelumbinis 6-10 weight portion, Radix Et Rhizoma Rhei 6-10 weight portion, Spora Lygodii 10-20 weight portion, Indigo Naturalis 5-10 weight portion.
3, Chinese medicine composition according to claim 1 is characterized in that this Chinese medicine composition made by following raw materials in weight portion medicine:
Rhizoma Coptidis 10 weight portions, Radix Paeoniae Rubra 20 weight portions, Plumula Nelumbinis 8 weight portions, Radix Et Rhizoma Rhei 8 weight portions, Spora Lygodii 15 weight portions, Indigo Naturalis 6 weight portions.
4, Chinese medicine composition according to claim 1 is characterized in that this Chinese medicine composition made by following raw materials in weight portion medicine:
Rhizoma Coptidis 8 weight portions, Radix Paeoniae Rubra 18 weight portions, Plumula Nelumbinis 8 weight portions, Radix Et Rhizoma Rhei 7 weight portions, Spora Lygodii 18 weight portions, Indigo Naturalis 7 weight portions.
5, Chinese medicine composition according to claim 1 is characterized in that this Chinese medicine composition made by following raw materials in weight portion medicine:
Rhizoma Coptidis 6 weight portions, Radix Paeoniae Rubra 18 weight portions, Plumula Nelumbinis 7 weight portions, Radix Et Rhizoma Rhei 7 weight portions, Spora Lygodii 13 weight portions, Indigo Naturalis 8 weight portions.
6, as the preparation method of any one Chinese medicine composition as described in the claim 1-5, it is characterized in that this may further comprise the steps:
A, get Rhizoma Coptidis, Radix Paeoniae Rubra, Plumula Nelumbinis mixed powder and be broken into coarse powder, add 10～16 times of water gagings and decoct each 1～3 hour 2～4 times, filter, collecting decoction, relative density is 1.08～1.14 extractum when being concentrated into 50 ℃, 50～70 ℃ of vacuum dryings are ground into fine powder, and are standby;
B, Radix Et Rhizoma Rhei, Indigo Naturalis, Spora Lygodii pulverizing medicinal materials are crossed 80 mesh sieves, and be standby;
C, with step a gained dry extract fine powder and step b gained medical material fine powder, mix homogeneously is made tablet, capsule, pill, granule, promptly.
7, as preparation method as described in the claim 6, it is characterized in that among the step a coarse powder being added 12 times of water gagings decocts 3 times, each 1 hour, filter, collecting decoction, relative density is 1.08～1.14 extractum when being concentrated into 50 ℃, 60 ℃ of vacuum dryings.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102116558A CN101683404B (en) | 2008-09-22 | 2008-09-22 | Traditional Chinese medicine composition for treating dampness and heat in liver and gallbladder and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102116558A CN101683404B (en) | 2008-09-22 | 2008-09-22 | Traditional Chinese medicine composition for treating dampness and heat in liver and gallbladder and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101683404A true CN101683404A (en) | 2010-03-31 |
| CN101683404B CN101683404B (en) | 2012-06-13 |
Family
ID=42046934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008102116558A Active CN101683404B (en) | 2008-09-22 | 2008-09-22 | Traditional Chinese medicine composition for treating dampness and heat in liver and gallbladder and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101683404B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1170559C (en) * | 2000-05-25 | 2004-10-13 | 黄亚平 | Capsule for removing heat from liver and detoxicating and its preparing process |
-
2008
- 2008-09-22 CN CN2008102116558A patent/CN101683404B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101683404B (en) | 2012-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022036779A1 (en) | Huashibaidu granule, preparation method therefor and anti-viral drug | |
| CN101310751A (en) | Traditional Chinese medicine composition for replenishing qi and blood, preparation method and quality control method thereof | |
| CN111729054A (en) | Dampness-resolving toxin-vanquishing traditional Chinese medicine composition, traditional Chinese medicine preparation, preparation method and application thereof | |
| CN114558094B (en) | Sanqi dampness eliminating formula and application thereof | |
| WO2021169682A1 (en) | Traditional chinese medicine composition, and preparation method therefor and application thereof | |
| CN102885928A (en) | Chinese medicinal injection for treating jaundice and preparation method thereof | |
| CN111920849B (en) | Traditional Chinese medicine composition and traditional Chinese medicine preparation containing same | |
| CN101683404B (en) | Traditional Chinese medicine composition for treating dampness and heat in liver and gallbladder and preparation method thereof | |
| CN112107662A (en) | Traditional Chinese medicine composition for treating chronic gastritis and precancerous lesions of gastric cancer and medicament and application thereof | |
| CN101618085B (en) | Traditional Chinese medicine composition for treating liver and gallbladder dampness-heat disease and preparation method thereof | |
| CN104042895A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof | |
| CN113577177B (en) | Traditional Chinese medicine composition containing red peony root and sargentgloryvine stem and preparation method and application thereof | |
| CN102362993B (en) | Chinese medicinal preparation with effects of protecting intestines and removing toxic materials, and preparation method thereof | |
| CN102641402A (en) | Preparation and quality control method of traditional Chinese medicine compound preparation for treating nephritis | |
| CN1136889C (en) | Instant particles as Chinese medicine for treating AIDS and its preparing process | |
| CN100491515C (en) | A kind of Cordyceps double ginseng wine | |
| CN117379505B (en) | A Chinese medicine composition for treating chronic kidney disease | |
| CN107233540A (en) | A kind of Chinese medicine composition for treating rheumatoid arthritis | |
| CN113559141B (en) | Application of artemisia capillaris for preparing medicine for treating pulmonary fibrosis | |
| CN116617319B (en) | A Chinese medicine composition for improving clinical symptoms of HIV infected persons, and its preparation and application | |
| CN100531749C (en) | A pharmaceutical composition for treating nephropathy and its preparation method | |
| CN100528191C (en) | Chinese medicine preparation for treating diabetes complication and its preparing method | |
| CN101637563A (en) | A Chinese medicinal composition for treating viral myocarditis, and its preparation method | |
| CN107737214A (en) | A kind of drug regimen for treating liver fibrosis and its preparation method and application | |
| CN116474036A (en) | A kind of traditional Chinese medicine composition and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |